Format | Price | Quantity | Select |
---|---|---|---|
PDF Download |
$6.95
|
||
Printed Black & White Copy |
$7.25
|
The chairman and CEO of the Genzyme Corporation, one of the country's top five biotechnology firms, has received a phone call requesting a meeting with the cofounder and principal of a large activist investment fund that now has a 2.6% stake in his company. Before meeting with him, the CEO is aware that he needs a strategy for dealing with this "activist" investor with a track record of forcing out CEOs.